Navigation Links
Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)
Date:9/26/2007

e scientific information discussed in this news release related to our product candidate is preliminary and investigative. The product candidate is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidate. Only the FDA can determine whether the product candidate is safe and effective for the use(s) being investigated. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on August 7, 2007 and is available from the SEC's website (http://www.sec.gov) and on our website (http://www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.

Contact:

Denise T. Powell

Sr. Director, Corporate Communications

Threshold Pharmaceuticals, Inc.

650-474-8206

dpowell@thresholdpharm.com


'/>"/>
SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Today the U.S. Food and Drug Administration ... prevention of serogroup B meningococcal disease in ... Trumenba®, which received FDA approval in October, represent a ... "I have heard over and over ...
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ... Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and ... Size, Share, Growth, Trends and Forecast 2014 - 2020" ... At present, the global market for urinary catheters is ...
(Date:1/23/2015)... Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... DCVax® personalized immune therapies for operable and inoperable solid tumor ... present at the 7 th Annual Phacilitate Immunotherapy Forum ... Bio,s presentation at Phacilitate will take place on January 26 ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... Nov. 9, 2011 Reportlinker.com announces ... is available in its catalogue: ... in Europe - Reference Pricing and ... Drugs Pose Significant Challenge to Pharmaceutical ...
... Company (NYSE: KV.A/ KV.B) (the "Company" or "K-V"), today reported ... Food & Drug Administration ("FDA") approved product indicated to reduce ... who have a history of a singleton spontaneous preterm birth. ... 2011. From its launch date through October 31, 2011: ...
Cached Medicine Technology:Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 2Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 3Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 4Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 5Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 6Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 7K-V Pharmaceutical Announces Updated Makena® Performance Metrics 2K-V Pharmaceutical Announces Updated Makena® Performance Metrics 3K-V Pharmaceutical Announces Updated Makena® Performance Metrics 4K-V Pharmaceutical Announces Updated Makena® Performance Metrics 5K-V Pharmaceutical Announces Updated Makena® Performance Metrics 6K-V Pharmaceutical Announces Updated Makena® Performance Metrics 7K-V Pharmaceutical Announces Updated Makena® Performance Metrics 8
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... January 22, 2015 JJsHouse.com is a famous ... Today, the business announces its latest collection of wedding ... “The most important issue is the wedding dress on your ... in a woman’s life. Every bride wants to find the ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... have discovered a key molecule needed to kill the blood ... institute,s Molecular Genetics of Cancer and Cancer and Haematology divisions ... to work the death- inducing molecule Bim is required. The ... on a two- or three-pronged attack on both the tumour ...
... researchers participated in more than 50 studies on improvements ... be presented at the 2011 Annual Meeting of the ... from June 3 through 7. Research highlights include: ... tumor response, adverse events and surgical complications in patients ...
... By Amanda Gardner HealthDay Reporter , SATURDAY, June ... common cancer drug, Avastin, may benefit both early stage ovarian ... In both studies, presented Saturday at the annual meeting of ... was added to standard chemotherapy. But the high ...
... the University of North Carolina at Chapel Hill School ... transplantation of adult stem cells enriched with a bone-regenerating ... not healing properly. The UNC study team led ... biomedical engineering, demonstrated that stem cells manufactured with the ...
... people with knee injuries could benefit from a new type ... The world,s first clinical trial for the treatment of patients ... regulatory agency, the MHRA1, to commence. The current ... the meniscus, a procedure that often results in the early ...
... indicates that longer time to beginning adjuvant chemotherapy after surgery ... a study in the June 8 issue of JAMA ... published early online to coincide with its presentation at the ... cancer (CRC) is the third leading cause of cancer mortality ...
Cached Medicine News:Health News:New strategy to attack tumor-feeding blood vessels 2Health News:City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO 2Health News:City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO 3Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 2Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 3Health News:Stem cell treatment may offer option for broken bones that don't heal 2Health News:Pioneering stem cell bandage receives approval for clinical trial 2Health News:Following colorectal cancer surgery, longer delay before chemotherapy associated with worse survival 2
... I system is a unique ... combines dual width capability with ... roll" design. Specifically developed to ... patients, the easy-to-use Tri-Flex I ...
... Max 10 Nebulizer W/ 7` CR Resistant ... for fast treatment times , ,Provide ... percentage of respirable particles) than conventional nebulizers, ... disposable nebulizers deliver fast and effective treatment ...
... 500ML 0.45% Sodium Chloride , ... ease of use. You can obtain heated and ... FIO 2 . We offer a wide selection ... sodium chloride inhalation, USP; and 0.9% sodium chloride ...
... Disposable Prefilled 28%-100% FIO 2 1000ML 0.45% ... ,Our prefilled nebulizers provide unmatched performance and ease ... high-output aerosols adjustable from 28% to 100% FIO ... solutions: sterile water for inhalation, USP; 0.45% sodium ...
Medicine Products: